Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel Aaron Zlotoff, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Daniel Zlotoff and Leyre Zubiri.
Connection Strength

0.993
  1. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.239
  2. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.231
  3. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022 Mar; 163:108-118.
    View in: PubMed
    Score: 0.061
  4. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021 Oct 15; 158:99-110.
    View in: PubMed
    Score: 0.060
  5. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv. 2021 Jan; 1(1):ltab014.
    View in: PubMed
    Score: 0.059
  6. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.059
  7. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Curr Treat Options Oncol. 2021 05 26; 22(6):53.
    View in: PubMed
    Score: 0.059
  8. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.058
  9. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306.
    View in: PubMed
    Score: 0.057
  10. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 12 15; 142(24):2299-2311.
    View in: PubMed
    Score: 0.056
  11. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034.
    View in: PubMed
    Score: 0.055
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.